Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHinneh, J.A.-
dc.contributor.authorGillis, J.L.-
dc.contributor.authorMoore, N.L.-
dc.contributor.authorButler, L.M.-
dc.contributor.authorCentenera, M.M.-
dc.identifier.citationFrontiers in Oncology, 2022; 12:982231-1-982231-14-
dc.descriptionPUBLISHED 10 August 2022-
dc.description.abstractReceptor for hyaluronic acid-mediated motility (RHAMM) is a cell surface receptor for hyaluronic acid that is critical for cell migration and a cell cycle protein involved in microtubule assembly and stability. These functions of RHAMM are required for cellular stress responses and cell cycle progression but are also exploited by tumor cells for malignant progression and metastasis. RHAMM is often overexpressed in tumors and is an independent adverse prognostic factor for a number of cancers such as breast and prostate. Interestingly, pharmacological or genetic inhibition of RHAMM in vitro and in vivo ablates tumor invasiveness and metastatic spread, implicating RHAMM as a potential therapeutic target to restrict tumor growth and improve patient survival. However, RHAMM's pro-tumor activity is dependent on its subcellular distribution, which complicates the design of RHAMM-directed therapies. An alternative approach is to identify downstream signaling pathways that mediate RHAMM-promoted tumor aggressiveness. Herein, we discuss the pro-tumoral roles of RHAMM and elucidate the corresponding regulators and signaling pathways mediating RHAMM downstream events, with a specific focus on strategies to target the RHAMM signaling network in cancer cells.-
dc.description.statementofresponsibilityJosephine A. Hinneh, Joanna L. Gillis, Nicole L. Moore, Lisa M. Butler and Margaret M. Centenera-
dc.publisherFrontiers Media-
dc.rights© 2022 Hinneh, Gillis, Moore, Butler and Centenera. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.-
dc.titleThe role of RHAMM in cancer: Exposing novel therapeutic vulnerabilities-
dc.typeJournal article-
dc.identifier.orcidHinneh, J.A. [0000-0003-0207-8453]-
dc.identifier.orcidButler, L.M. [0000-0003-2698-3220]-
dc.identifier.orcidCentenera, M.M. [0000-0002-2206-0632]-
Appears in Collections:Medicine publications
South Australian Immunogenomics Cancer Institute (SAIGENCI) publications

Files in This Item:
File Description SizeFormat 
hdl_136969.pdfPublished version3.25 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.